The PROBLEM with both COVID studies is neither one of them were designed to move beyond Phase 2. Meaning, they were just show trials. The same thing goes for the IPF/Chronic Cough study. It's a show trial. The data to run a legitimate Chronic Cough study powered for statistical significance already exists within the preclinical trial data purchased from Nash Pharmaceuticals in the reverse takeover of Breathtec Biomedical (now named Algernon Pharmaceuticals) back in 2018. The history is all there. I'm not here to revise any of it's pure evil and ugliness. The COVID studies took us deep into dilution status. Bottom line is we got fucked by management and they are not done yet.
News 
Market Data 
Discover 
